Chemical Modification of Leukotriene A4 Hydrolase. Indications for Essential Tyrosyl and Arginyl Residues at the Active Site

Biochemistry ◽  
1995 ◽  
Vol 34 (11) ◽  
pp. 3536-3543 ◽  
Author(s):  
Martin J. Mueller ◽  
Bengt Samuelsson ◽  
Jesper Z. Haeggstroem
Keyword(s):  
Chemical Modification ◽  
Active Site ◽  
Leukotriene A4 Hydrolase ◽  
Leukotriene A4 ◽  
Arginyl Residues

scholarly journals Structure-Based Dissection of the Active Site Chemistry of Leukotriene A4 Hydrolase: Implications for M1 Aminopeptidases and Inhibitor Design

2008 ◽  
Vol 15 (9) ◽  
pp. 920-929 ◽  
Author(s):  
Fredrik Tholander ◽  
Ayumo Muroya ◽  
Bernard-Pierre Roques ◽  
Marie-Claude Fournié-Zaluski ◽  
Marjolein M.G.M. Thunnissen ◽  
...  
Keyword(s):  
Active Site ◽  
Inhibitor Design ◽  
Leukotriene A4 Hydrolase ◽  
Leukotriene A4

Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A4 Hydrolase

2021 ◽  
Vol 64 (4) ◽  
pp. 1889-1903
Author(s):  
Christian Markert ◽  
Gebhard Thoma ◽  
Honnappa Srinivas ◽  
Birgit Bollbuck ◽  
Rainer M. Lüönd ◽  
...  
Keyword(s):  
Selective Inhibitor ◽  
Leukotriene A4 Hydrolase ◽  
Leukotriene A4

Identification of modulating residues defining the catalytic cleft of insulin-regulated aminopeptidase

2008 ◽  
Vol 86 (3) ◽  
pp. 251-261 ◽  
Author(s):  
Siying Ye ◽  
Siew Yeen Chai ◽  
Rebecca A. Lew ◽  
David B. Ascher ◽  
Craig J. Morton ◽  
...  
Keyword(s):  
Catalytic Domain ◽  
Substrate Affinity ◽  
Angiotensin Iv ◽  
Peptide Substrates ◽  
Fold Reduction ◽  
Leukotriene A4 Hydrolase ◽  
Substrate Cleavage ◽  
Leukotriene A4 ◽  
Key Residues ◽  
Catalytic Cleft

Inhibition of insulin-regulated aminopeptidase (IRAP) has been demonstrated to facilitate memory in rodents, making IRAP a potential target for the development of cognitive enhancing therapies. In this study, we generated a 3-D model of the catalytic domain of IRAP based on the crystal structure of leukotriene A4 hydrolase (LTA4H). This model identified two key residues at the ‘entrance’ of the catalytic cleft of IRAP, Ala427 and Leu483, which present a more open arrangement of the S1 subsite compared with LTA4H. These residues may define the size and 3-D structure of the catalytic pocket, thereby conferring substrate and inhibitor specificity. Alteration of the S1 subsite by the mutation A427Y in IRAP markedly increased the rate of substrate cleavage V of the enzyme for a synthetic substrate, although a corresponding increase in the rate of cleavage of peptide substrates Leu-enkephalin and vasopressin was was not apparent. In contrast, [L483F]IRAP demonstrated a 30-fold decrease in activity due to changes in both substrate affinity and rate of substrate cleavage. [L483F]IRAP, although capable of efficiently cleaving the N-terminal cysteine from vasopressin, was unable to cleave the tyrosine residue from either Leu-enkephalin or Cyt6-desCys1-vasopressin (2–9), both substrates of IRAP. An 11-fold reduction in the affinity of the peptide inhibitor norleucine1-angiotensin IV was observed, whereas the affinity of angiotensin IV remained unaltered. In additionm we predict that the peptide inhibitors bind to the catalytic site, with the NH2-terminal P1 residue occupying the catalytic cleft (S1 subsite) in a manner similar to that proposed for peptide substrates.

Sign in / Sign up

Export Citation Format

Share Document